JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.

Abstract

Continuous ruxolitinib therapy, as compared with the best available therapy, was associated with marked and durable reductions in splenomegaly and disease-related symptoms, improvements in role functioning and quality of life, and modest toxic effects.

An influence on overall survival has not yet been shown. (Funded by Novartis Pharmaceuticals; ClinicalTrials.gov number, NCT00934544.).

Full Text

• DOI - The New England journal of medicine (DOI)
• Swets Information Services - full-text online
• Ovid Technologies, Inc. - full-text online
• EBSCO - full-text online
• Atypon - full-text online

Subjects

• Adult
• Aged
• Aged, 80 and over
• Cause of Death
• Female
• Follow-Up Studies
• Humans
• Janus Kinase 1
• Janus Kinase 2
• Male
• Middle Aged
• Organ Size
• Primary Myelofibrosis
• Protein Kinase Inhibitors
• Pyrazoles
• Quality of Life
• Spleen
• Splenomegaly
• Survival Analysis

Similar articles

• Ruxolitinib for myelofibrosis. (2013-01-07)
• Ruxolitinib: in the treatment of myelofibrosis. (2012-10-16)
• Health-related quality of life and symptoms in patients with myelofibrosis treated with ruxolitinib versus best available therapy. (2013-05-14)
• Ruxolitinib: an oral Janus kinase 1 and Janus kinase 2 inhibitor in the management of myelofibrosis. (2013-02-08)
• Ruxolitinib: a new treatment option for myelofibrosis. (2013-01-11)
• JAK inhibitors for myeloproliferative neoplasms: clarifying facts from myths. (2012-03-23)
• Advances in the management of myelofibrosis. (2012-10-08)
• Biology and clinical management of myeloproliferative neoplasms and development of the JAK inhibitor ruxolitinib. (2012-04-13)
• A comprehensive review and analysis of the effect of ruxolitinib therapy on the survival of patients with myelofibrosis. (2013-04-09)

Authors

• Claire Harrison
• Jean-Jacques Kiladjian
• Haifa Kathrin Al-Ali
• Heinz Gisslinger
• Roger Waltzman
• Viktoriya Stalbovskaya
• Mari McQuitty
• Deborah S Hunter
• Richard Levy
• Laurent Knoops
• Francisco Cervantes
• Alessandro M Vannucchi
• Tiziano Barbui
• Giovanni Barosi

Publication date

2012-03-01

Journal

Journal topics

• Medicine

Language

Eng.

Copyright

The New England journal of medicine

Guy's and St. Thomas' National Health Service Foundation Trust, Guy's Hospital, London, United Kingdom. claire.harrison [at] gstt.nhs.uk

Release reference

N Engl J Med. 2012 Mar;366(9):787-98

Related books

• Books of Cause of Death
• Books of Follow-Up Studies
• Books of Janus Kinase 1
• Books of Janus Kinase 2
• Books of Medicine
• Books of Organ Size
• Books of Primary Myelofibrosis
• Books of Protein Kinase Inhibitors
• Books of Pyrazoles
• Books of Quality of Life
• Books of Spleen
• Books of Splenomegaly
• Books of Survival Analysis